{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:01:22Z","timestamp":1775062882356,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81774044"],"award-info":[{"award-number":["81774044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific research and innovation team project of Beijing University of Chinese Medicine","award":["2019-JYB-TD-008"],"award-info":[{"award-number":["2019-JYB-TD-008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Backgroud<\/jats:title>\n<jats:p>Xuezhitong (XZT) is an extract of Allium macrostemon Bunge that has lipid-lowering properties.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>To evaluate the effects of XZT on lipids in subjects with hypertriglyceridemia (HTG) without severe dyslipidaemia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A total of 358 subjects with HTG were enrolled and randomly assigned to receive XZT (2700\u00a0mg daily), xuezhikang (XZK) (1200\u00a0mg daily) or placebo. The primary endpoint was the reduction or percent reduction in the TG level over 12\u00a0weeks of treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>At the 12-week follow-up, a reduction in the TG level from baseline was observed in both groups, but the XZT and XZK groups demonstrated a significantly greater reduction than the placebo group (30.77%, 24.02% vs 11.59%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0167); 70.54% of subjects in the XZT group and 62.30% of subjects in the XZK group demonstrated reductions in TG levels of at least 20%, compared with 41.67% of the subjects in the placebo group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0167). Treatment with XZT capsules also demonstrated superior performance compared with the placebo with respect to the control of lipids (17.97% vs 5.00%), total cholesterol (TC) (14.18% vs 3.89%), low-density lipoprotein cholesterol (LDL-C) (17.98% vs 2.95%), and high-density lipoprotein cholesterol (HDL-C) (21.47% vs 2.16%). Daily use of XZT for 12\u00a0weeks resulted in statistically significant (65.22% vs 38.30%, 25.00%; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0167) and clinically meaningful increases in HDL-C levels by \u22654\u00a0mg\/dl compared with XZK and placebo. XZT was safe and well tolerated; the safety and tolerability profiles were similar across treatment groups. No subject experienced myopathy or markedly elevated liver transaminases or creatine kinase.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>XZT significantly reduced TG levels and was well tolerated. Longer-term studies in more diverse patient populations are needed to corroborate these findings.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Clinical Trial Registration<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\">www.chictr.org.cn<\/jats:ext-link> Identifier: ChiCTR1900025854.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10557-020-06965-3","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T08:02:28Z","timestamp":1584950548000},"page":"525-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of Xuezhitong in Patients with Hypertriglyceridemia: a Multicentre, Randomized, Double-Blind, Double Simulation, Positive Drug and Placebo Parallel Control Study"],"prefix":"10.1007","volume":"34","author":[{"given":"Wenhao","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"6965_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pcad.2019.11.005","volume":"62","author":"NJ Stone","year":"2019","unstructured":"Stone NJ, Grundy SM. The 2018 AHA\/ACC\/multi-society cholesterol guidelines: looking at past, present and future. Prog Cardiovasc Dis. 2019;62:375\u201383.","journal-title":"Prog Cardiovasc Dis"},{"key":"6965_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","volume":"14","author":"UK Sampson","year":"2012","unstructured":"Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1\u201310.","journal-title":"Curr Atheroscler Rep"},{"key":"6965_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.atherosclerosis.2016.02.006","volume":"248","author":"L Pan","year":"2016","unstructured":"Pan L, Yang ZH, Wu Y, Yin RX, Liao YH, Wang JW, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis. 2016;248:2\u20139.","journal-title":"Atherosclerosis"},{"key":"6965_CR4","doi-asserted-by":"publisher","first-page":"e008740","DOI":"10.1161\/JAHA.118.008740","volume":"7","author":"PP Toth","year":"2018","unstructured":"Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7:e008740.","journal-title":"J Am Heart Assoc"},{"key":"6965_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dom.13537","volume":"21","author":"GA Nichols","year":"2019","unstructured":"Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2019;21:366\u201371.","journal-title":"Diabetes Obes Metab"},{"key":"6965_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1476-511X-12-159","volume":"12","author":"J Liu","year":"2013","unstructured":"Liu J, Zeng FF, Liu ZM, Zhang CX, Ling WH, Chen YM. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis. 2013;12:159.","journal-title":"Lipids Health Dis"},{"key":"6965_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of endocrinology guidelines for Management of Dyslipidemia and Prevention of cardiovascular disease. Endocr Pract. 2017;23:1\u201387.","journal-title":"Endocr Pract"},{"key":"6965_CR8","first-page":"481","volume":"14","author":"ZH Yao","year":"2016","unstructured":"Yao ZH, Qin ZF, Dai Y, Yao XS. Phytochemistry and pharmacology of Allii Macrostemonis Bulbus, a traditional Chinese medicine. Chin J Nat Med. 2016;14:481\u201398.","journal-title":"Chin J Nat Med"},{"key":"6965_CR9","first-page":"108","volume":"13","author":"ZL Li","year":"2013","unstructured":"Li ZL. Evaluation on the clinical application of Xuezhitong capsule. Eval Anal Drug Use Hosp China. 2013;13:108\u20139.","journal-title":"Eval Anal Drug Use Hosp China"},{"key":"6965_CR10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3389\/fphar.2019.01449","volume":"10","author":"B Zhu","year":"2019","unstructured":"Zhu B, Qi F, Wu J, Yin G, Hua J, Zhang Q, et al. Red yeast Rice: a systematic review of the traditional uses, chemistry, pharmacology, and quality control of an important Chinese folk medicine. Front Pharmacol. 2019;10:1449.","journal-title":"Front Pharmacol"},{"key":"6965_CR11","first-page":"51","volume":"16","author":"SD Zheng","year":"2019","unstructured":"Zheng SD, Yang C, Zhang CY. Meta-analysis of Xuezhikang capsules in the treatment of patients with dyslipidemia. China Med Herald. 2019;16:51\u20135.","journal-title":"China Med Herald"},{"key":"6965_CR12","first-page":"117","volume":"4","author":"RX Xu","year":"2018","unstructured":"Xu RX, Zhang Y, Guo YL, Ma CY, Yao YH, Li S, et al. Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans. Chronic Dis Transl Med. 2018;4:117\u201326.","journal-title":"Chronic Dis Transl Med"},{"key":"6965_CR13","first-page":"5","volume":"26","author":"GZ Liu","year":"1998","unstructured":"Liu GZ, Wu N, Hu DY, Tao P, Zhu JR, Guo LN, et al. Suggestions on evaluation methods of clinical trials of cardiovascular drugs. Chin J Cardiol. 1998;26:5\u201313.","journal-title":"Chin J Cardiol"},{"key":"6965_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11655-010-0119-7","volume":"16","author":"XF Fan","year":"2010","unstructured":"Fan XF, Deng YQ, Ye L, Li YD, Chen J, Lu WW, et al. Effect of Xuezhikang capsule on serum tumor necrosis factor-\u03b1 and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chin J Integr Med. 2010;16:119\u201323.","journal-title":"Chin J Integr Med"},{"key":"6965_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0021-9150(01)00700-6","volume":"162","author":"M Schweitzer","year":"2002","unstructured":"Schweitzer M, Tessier D, Vlahos WD, Leiter L, Collet JP, McQueen MJ, et al. A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis. 2002;162:201\u201310.","journal-title":"Atherosclerosis"},{"key":"6965_CR16","first-page":"414","volume":"46","author":"JH Li","year":"2012","unstructured":"Li JH, Wang LM, Li YC, Bi YF, Jiang Y, Mi SQ, et al. Epidemiologic characteristics of dyslipidemia in Chinese adults in 2010. Chin J Prev Med. 2012;46:414\u20138.","journal-title":"Chin J Prev Med"},{"key":"6965_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","volume":"235","author":"SQ Zhao","year":"2014","unstructured":"Zhao SQ, Wang YJ, Mu YM, Yu BL, Ye P, Yan XW, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia international study (DYSIS). Atherosclerosis. 2014;235:463\u20139.","journal-title":"Atherosclerosis"},{"key":"6965_CR18","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","volume":"65","author":"GG Schwartz","year":"2015","unstructured":"Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65:2267\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"6965_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1210\/er.2018-00184","volume":"40","author":"PB Sandesara","year":"2019","unstructured":"Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019;40:537\u201357.","journal-title":"Endocr Rev"},{"key":"6965_CR20","first-page":"1051","volume":"376","author":"J Min","year":"2010","unstructured":"Min J, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;376:1051\u20132.","journal-title":"Lancet"},{"key":"6965_CR21","first-page":"1137","volume":"11","author":"FX Qiao","year":"2016","unstructured":"Qiao FX, Cai H, Fei K, Song XQ, Fan QK. Research Progress of Allii Macrostemonis Bulbus. World Chinese Med. 2016;11:1137\u201340.","journal-title":"World Chinese Med"},{"key":"6965_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jacl.2014.09.002","volume":"8","author":"PM Moriarty","year":"2014","unstructured":"Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, et al. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. J Clin Lipidol. 2014;8:568\u201375.","journal-title":"J Clin Lipidol"},{"key":"6965_CR23","doi-asserted-by":"publisher","first-page":"e0184949","DOI":"10.1371\/journal.pone.0184949","volume":"12","author":"SP Zhao","year":"2017","unstructured":"Zhao SP, Li R, Dai W, Yu BL, Chen LZ, Huang XS. Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARalpha signaling pathway. PLoS One. 2017;12:e0184949.","journal-title":"PLoS One"},{"key":"6965_CR24","doi-asserted-by":"publisher","first-page":"e82046","DOI":"10.1371\/journal.pone.0082046","volume":"8","author":"A Nakamura","year":"2013","unstructured":"Nakamura A, Niimura H, Kuwabara K, Takezaki T, Morita E, Wakai K, et al. Gene-gene combination effect and interactions among ABCA1, APOA1, SR-B1, and CETP polymorphisms for serum high-density lipoprotein-cholesterol in the Japanese population. PLoS One. 2013;8:e82046.","journal-title":"PLoS One"},{"key":"6965_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21037\/atm.2019.04.77","volume":"7","author":"XB Meng","year":"2019","unstructured":"Meng XB, Zhu T, Yang DH, Liang W, Sun GB, Sun XB. Xuezhitong capsule, an extract of Allium macrostemon Bunge, exhibits reverse cholesterol transport and accompanies high-density lipoprotein levels to protect against hyperlipidemia in ApoE(\u2212\/\u2212) mice. Ann Transl Med. 2019;7:239.","journal-title":"Ann Transl Med"},{"key":"6965_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvy029","volume":"4","author":"J Hallen","year":"2018","unstructured":"Hallen J, Sreeharan N. Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations. Eur Heart J Cardiovasc Pharmacother. 2018;4:237\u201342.","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-020-06965-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:06:33Z","timestamp":1616457993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-020-06965-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["6965"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-06965-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"23 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study conformed to the ethical tenets originating in the Declaration of Helsinki, International Conference on Harmonization\/Good Clinical Practice (ICH\/GCP) guidelines and to applicable local regulatory requirements and laws. All study candidates provided written informed consent before engaging in any study activity. The consent document, protocol, and all amendments were reviewed and approved by local institutional review boards in China.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}